+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06983821

Study of Low-Dose Glucocorticoid with Cyclophosphamide and Rituximab for Severe ANCA-Associated Vasculitis Affecting the Kidneys

Led by Ottawa Hospital Research Institute · Updated on 2026-01-30

36

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety and effectiveness of a new treatment plan using a short 4-week course of glucocorticoids combined with usual induction drugs for ANCA-associated vasculitis AAV, a serious autoimmune disease that often affects the kidneys. The study compares this approach to the current standard treatment, focusing on patients with severe kidney involvement. The trial begins as a pilot to test if patients can be recruited and follow the treatment plan properly. The study includes two groups one receives two doses of intravenous cyclophosphamide combined with rituximab and a 4-week prednisone taper, while the other group receives standard care with induction agents and glucocorticoid doses chosen by their doctor. This pilot phase assesses feasibility and adherence, with potential expansion to a full trial if successful. Participants will be monitored for adherence to the treatment during the first 12 weeks, and the full trial will measure the rate of serious infections and remission at 26 weeks. Researchers will collect health data and track safety throughout the study, which is expected to continue until early 2029. The goal is to find a regimen that reduces steroid side effects and infection risk while effectively controlling the disease.

CONDITIONS

Brief Title

Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)

Research Team

D

David Massicotte-Azarniouch, MD, MSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here